Patricia Silva, PhD,  director of science content—

Holidays abroad may hold the key to tackling Scotland’s vitamin D deficiency, a University of Edinburgh study suggests. The study, “Farming, Foreign Holidays, and Vitamin D in Orkney,” was published in the journal PloS One. Multiple sclerosis (MS) is a chronic, complex disease…

A case report of a woman with relapsing-remitting multiple sclerosis (MS), who developed progressive multifocal leukoencephalopathy (PML) after natalizumab therapy, found that the immune-boosting molecule interleukin-2 (IL-2) might be a viable therapeutic option to fight this life-threatening complication although further study is needed. The case report, “Use of interleukin-2 for…

Sanofi Genzyme announced that it entered into a research collaboration with the Johns Hopkins School of Medicine to better understand the underlying causes of disease progression in multiple sclerosis (MS). Sanofi Genzyme has a number of research partnerships with MS academic medical centers, focused on exploring the pathogenesis of MS and potential new…

With an interest multiple sclerosis (MS) before even starting college, Dr. Ellen Mowry has spent her entire research career investigating the disease. Her epidemiological studies led her to indications that vitamin D might be particularly important for people with MS, and she now dedicates her research to the topic — knowledge she will share at the…

LyondellBasell, an established name in the plastics, chemical and refining industry, has been honored with the Circle of Distinction Award from the National Multiple Sclerosis Society for raising $1.4 million to benefit the society and the multiple sclerosis (MS) community. Since 1998, the company has participated in the MS Society’s annual fundraiser in…

A substance called fluorosamine was seen to boost remyelination in mice by preventing the synthesis of chondroitin sulfate proteoglycans and by promoting oligodendrocyte function. The findings showed that targeting molecules that block remyelination may be a promising therapeutic approach in multiple sclerosis (MS). Upregulation of chondroitin sulfate proteoglycans — large molecules…

Rebound symptoms after stopping fingolimod (Gilenya) treatment affect a “clinically relevant” number of multiple sclerosis (MS) patients, a study by University of California, San Francisco, researchers reported. The study called attention to the need for determining the best method of sequencing or stopping MS treatments, and highlighted the need to identify factors…

Canadian Prime Minister Justin Trudeau and other lawmakers met with members of the multiple sclerosis (MS) community and the Multiple Sclerosis Society of Canada (MSSC) at the start of May, MS Awareness Month, to discuss issues of importance to those living with the disease. From left: Hedy Fry, a member of Parliament;…

Patients with multiple sclerosis (MS) have increased levels of the neurotransmitter glutamate in their brains, lowering the levels of N-acetylaspartate (NAA) — a process that likely leads to the loss of brain volume. The findings indicate that glutamate might be a driver of neuronal cell death and disease progression in MS,…

Exercises like yoga and aquatic programs can help ease some symptoms of multiple sclerosis (MS), especially fatigue, depression and paresthesia, researchers report in a study published in the journal Medicine & Science in Sports & Exercise, and titled “Exercising Impacts on Fatigue, Depression, and Paresthesia in Female Patients with Multiple…

Clinical results presented at the recent Academy of Managed Care Pharmacy (AMCP)‘s 2016 annual meeting in San Francisco showed that the use of H.P. Acthar Gel during multiple sclerosis (MS) relapses is associated with beneficial outcomes. The gel, according to its producer, is also available at a lower price than other frequently used…

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently recommended marketing authorization to Zinbryta (daclizumab) for the treatment of patients with relapsing multiple sclerosis (RMS). Zinbryta (daclizumab HYP) is a humanized monoclonal antibody that is injected every four weeks, and being developed by…

The National Multiple Sclerosis Society has awarded Dr. Bart Rypma, an associate professor at the Center for BrainHealth at the University of Texas at Dallas, a more than $490,000 grant to study how changes in blood flow in the brain might affect cognition in people with multiple sclerosis (MS). The grant builds on previous research…

A gift worth $185 million from Joan and Sanford I. Weill to the University of California San Francisco (UCSF) will allow the university to expand its neurosciences programs and facilities, advancing its research work into psychiatric, neurological and neurodegenerative diseases, including multiple sclerosis (MS). The gift, the largest single donation in UCSF history, is…

Researchers at Purdue University have developed a method of identifying subtle oscillations in a person’s posture that mirror an excessive delay in neuromuscular responses, indicating a neurologic deficit. The oscillations, which differ from the normal tendency of a standing person to sway, may aid in diagnosing neuromuscular disorders such as multiple sclerosis (MS).

The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) is making available to qualified researchers a new database containing almost 2,500 records of patients who were part of the placebo groups of nine multiple sclerosis (MS) studies. The MSOAC is a large-scale partnership, launched by the National MS Society and Critical…

In a study published in the International Neurology Journal, researchers showed that cognitive deficits, such as memory problems, in a rat model of multiple sclerosis (MS) are mirrored by changes in synaptic transmission and plasticity in the hippocampus, a brain region crucial for memory processing. The findings…

Researchers at the Center of Excellence for Myelin Repair, a part of Mount Sinai, reported that gut bacteria produce compounds that were seen to affect the myelin content in mice and cause social avoidance behaviors. Study results indicated that targeting gut bacteria, or the gut metabolites, might help in treating neuropsychiatric disorders or complications, such as those…

MedDay recently disclosed full study results from the MS-SPI and MS-ON Phase 2b/3 trials of its therapeutic candidate MD1003 in patients with multiple sclerosis (MS). Specifically, the trials included people with “not active” progressive MS and those with either relapsing or progressive MS and visual loss, respectively. Data, presented at the recent American…

Researchers at the School of Medicine of the University of California (UC), Riverside, found that TNF-alpha, a factor known for its pro-inflammatory actions, also triggers processes that end inflammation by inducing a type of immune surveillance cell, called M-cells. By advancing our understanding of immune processes, the finding may lead to…

Multiple sclerosis patients using a cognitive remediation computer training program, part of a controlled trial by researchers from NYU Langone Medical Center, had greater improvements in cognitive function than those who used a placebo-training program, according to a presentation at the recent American Academy of Neurology annual meeting in Vancouver, Canada. Problems in attention, memory,…

A roundtable discussion, provided as a webinar organized by the Consortium of Multiple Sclerosis Centers (CMSC) in advance of its June conference, considered the role of vitamin D in multiple sclerosis (MS). Researchers concluded that, while evidence is only circumstantial as to the vitamin’s ability to prevent disease relapses, its multiple health benefits justify…

New data presented by Biogen and AbbVie at the recent 68th annual meeting of the American Academy of Neurology (AAN) showed that Zinbryta (daclizumab high-yield process) improved cognitive outcome measures in patients with relapsing forms of multiple sclerosis (RMS). Additional results — from post-hoc analyses of clinical trials — also offer a better…

Mabthera (rituximab), a widely approved drug for treating lymphoma and/or rheumatoid arthritis, is highly effective in treating multiple sclerosis (MS), researchers reported in an observational study in Sweden, where Mabthera is increasingly being used outside of its approved indications to treat relapsing-remitting MS patients. The study, published in the journal…

The National Multiple Sclerosis Society and Event360 announced the opening of the 2016 season of MuckFest MS, a 5K “mud run” and fundraiser with over 20 obstacles along its course to challenge and entertain people of all athletic levels. This year’s run will take place in 11 cities across the U.S., including a…

The Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting will open with the John F. Kurtzke Memorial Lecture, “Do Relapses Really Matter?”, by the renowned multiple sclerosis (MS) expert Dr. Fred D. Lublin of Mount Sinai Medical Center. The June 1 lecture offers a fresh view on recent evidence into the impact…

Sanofi Genzyme will present new data on its approved multiple sclerosis (MS) treatments — Lemtrada (alemtuzumab) and Aubagio (teriflunomide) — at the 68th annual meeting of the American Academy of Neurology (AAN), taking place in Vancouver, Canada, through April 21, as well as data on investigational therapies in its pipeline. In total, the meeting…

Innate Immunotherapeutics, Ltd., announced that it has completed patient enrollment in its ongoing Phase 2B, placebo-controlled clinical trial assessing the efficacy and safety of the drug MIS416 as a once-weekly treatment for secondary progressive multiple sclerosis (SPMS). MIS416 is a biologically derived immune modulator that targets myeloid cells, a subset of innate immune cells that can…

Teva Pharmaceutical Industries, Ltd., announced that new data on four of its products, including an approved and a potential treatment for multiple sclerosis, will be presented at the 68th Annual Meeting of the American Academy of Neurology (AAN), running through April 21 in Vancouver, Canada. The data, to be…

Genentech announced that it will present new data from three Phase 3 clinical trials of its experimental multiple sclerosis (MS) therapy Ocrevus (ocrelizumab) at the 68th annual meeting of the American Academy of Neurology (AAN) being held in Vancouver, Canada, from April 15–21, 2016. Additionally, results of a new endpoint for…